Last reviewed · How we verify
IBI355
At a glance
| Generic name | IBI355 |
|---|---|
| Sponsor | Innovent Biologics (Suzhou) Co. Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety and Tolerability of IBI355 in Patients With Primary Sjogren's Syndrome (PHASE1)
- Safety and Tolerability of IBI355 in Healthy Volunteers (PHASE1)
- Safety and Tolerance Study of IBI355 in Health Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IBI355 CI brief — competitive landscape report
- IBI355 updates RSS · CI watch RSS
- Innovent Biologics (Suzhou) Co. Ltd. portfolio CI